Our newest board member Fenel Eloi was just featured in BioPharma-Reporter. You can read more about Fenel's career and his role at Vaxess here: biopharma-reporter.com/Article/2022/1…

Thanks FiercePharma for the excellent coverage of our Phase 1 Trial of the MIMIX patch. Read the full article here: Vaxess' flu vaccine patch passes early clinical test, clearing path for further development fiercepharma.com/pharma/vaxess-…

Thank you to the Boston Business Journal for the awesome write-up on our final tranche payment, which came as a result of the promising interim results from our phase 1 clinical trial of the MIMIX-Flu patch. Read the full article here: bizjournals.com/boston/news/20…

Check out Built In Boston 's latest coverage the $10M tranche Vaxess recently received as a result of our positive interim clinical results. Read the full article here: builtinboston.com/2023/01/11/vax…

Thank you to Ladderworks x Nasdaq for chatting with Michael A. Schrader to discuss how Vaxess is disrupting the healthcare industry in a young entrepreneur friendly format! Read the full interview on Spiffy's blog here: nasdaq.com/articles/micha…

An interesting read on the progress being made in the vaccine space. Thank you to Korea Biomedical Review for featuring Vaxess in their latest feature on vaccine patch developments. Read the full article here: koreabiomed.com/news/articleVi…

Steve Bende, PhD, recently joined the Vaxess team as Chief Strategy Officer. Thank you to Drug Delivery Business News for sharing our exciting announcement. Read the full article here: drugdeliverybusiness.com/vaxess-former-… Drug Delivery Business News

Next week, Vaxess CEO Michael A. Schrader will be speaking at World Vaccine Congress about clinical results from Vaxess’s patch-based influenza vaccine. Read more about World Vaccine Congress and Michael’s session here — terrapinn.com/conference/wor…

The Vaxess team was honored to present at this year’s World Vaccine Congress. Our CEO Michael A. Schrader spoke about how Vaxess’s sustained release patch technology has the potential to fundamentally change how numerous vaccines are distributed and administered. #WVCUSA #wvc2023

Thank you to Bio-IT World for sharing our exciting mRNA stability results from tests assessing the potential for room-temperature storage. Read the full release here: bio-itworld.com/pressreleases/…

Thank you to BIO Convention (BIO.news) for providing Vaxess CEO, Michael A. Schrader , with the space to discuss why a vaccine patch could be a game changer for getting vaccination numbers up. Read the byline here: bio.news/health/vaccine…

Vaxess is thrilled to announce that it’s been recognized on the 2023 Impact/100, an annual list of the world’s most promising impact startups, compiled by Norrsken and its nomination partners. Read more about the Impact/100 below norrsken.org/impact100

We're excited to work with AstraZeneca to make the next generation of mRNA pandemic response vaccines more stable, more well tolerated, and accessible to patients at home. Thanks to Ryan Cross the Science Boss and Endpoints News for the coverage.

Vaxess is collaborating with AstraZeneca for the evaluation of an RNA-based pandemic influenza prototype vaccine in patch format. Through the collaboration, Vaxess could receive up to $10.3 million. Read more about today’s news in Endpoints News —endpts.com/exclusive-astr…

Vaxess is pleased to announce that we raised an additional $9M. This funding will be used to accelerate mRNA vaccine development on the MIMIX patch. Read more about the news on: Pharma Technology Focus pharmaceutical-technology.com/news/vaxess-ra…

Thank you to Drug Delivery Business News for the coverage on our exciting funding announcement! Read the full release here: drugdeliverybusiness.com/vaxess-raises-…

Thank you to BioPharma-Reporter for the feature on our recent funding announcement! Read the full article here: biopharma-reporter.com/Article/2023/0…

Vaxess raises $9M for mRNA vaccine patch that could revolutionize delivery #mrnavaccines #VaxessTechnologies #VaccinePatch #biotech #globalhealt #newtechnology #pharma #SilkFibroin #pharmaceuticaltechnology #GlobalData #partnership #astrazeneca #Microneedles Vaxess Technologies

We're very excited to announce that Vaxess has been recognized as a leading biotech company in BostInno 's 2023 Fire Awards! Read the full release here: vaxess.com/news-vaxess-ho…

We're incredibly honored to announce that Vaxess has been named "Vaccine Innovation of the Year" in the 2023 BioTech Breakthrough Awards for our progress on the MIMIX vaccine patch. Read more about the Biotech Breakthrough Awards Tech Breakthrough here: biotechbreakthroughawards.com/2023-winners/